Uracil (UFT, Tegafur-Uracil combinations)
Other Medications · Approved since 2001
Description
Uracil is a pyrimidine nucleobase that serves as a modulating agent used in combination with tegafur (5-fluorouracil prodrug) in oral fluoropyrimidine-based chemotherapy regimens for colorectal cancer. It functions as a competitive inhibitor of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in fluoropyrimidine catabolism, thereby enhancing the bioavailability and efficacy of 5-fluorouracil. This combination is particularly relevant in metastatic colorectal cancer treatment and is used across different molecular subtypes including microsatellite stable (MSS) and microsatellite instability-high (MSI-H) tumors.
Mechanism of Action
Uracil competitively inhibits dihydropyrimidine dehydrogenase (DPD), the primary enzyme responsible for the rapid degradation of 5-fluorouracil and its prodrugs. By blocking this catabolic pathway, uracil increases the systemic exposure and tumor concentration of active fluoropyrimidine metabolites that interfere with DNA synthesis and repair. This mechanism is particularly important in patients with high DPD activity, where pharmacogenomic testing may guide dosing adjustments to optimize therapeutic outcomes while minimizing toxicity.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | UFT, Tegafur-Uracil combinations |
| Category | Other Medications |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS approved in CRC |
| Administration | Oral |
| Year Approved | 2001 |
| Clinical Trials | 785 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.